Scleroderma is associated with differences in individual routes of drug metabolism

A study with dapsone, debrisoquin, and mephenytoin

D. Gail May, Carol M. Black, Nancy Olsen, Mary E. Csuka, S. Bobo Tanner, Lisa Bellino, James A. Porter, Grant R. Wilkinson, Robert A. Branch

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Exposure to certain environmental agents may induce a scleroderma-like syndrome in a small proportion of individuals. Differences in susceptibility could involve metabolic activation of a protoxin, with affected patients having a greater converting ability. This possibility was investigated in 84 patients with scleroderma and 108 control subjects with in vivo probes of specific pathways of metabolism. Scleroderma was associated with reduced hydroxylating activity for dapsone and S-mephenytoin, whereas the ability to hydroxylate debrisoquin and N-acetyl dapsone was similar in both groups. Logistic regression confirmed these associations based on the shift in frequency distribution. Individuals who were poor metabolizers for mephenytoin and only modest N-hydroxylators of dapsone had a tenfold increased risk of scleroderma (p = 0.008). Thus this combined metabolic impairment may be causally involved in the development of scleroderma or, alternatively, the disease may produce inhibition of selected metabolizing enzymes in a subset of patients.

Original languageEnglish (US)
Pages (from-to)286-295
Number of pages10
JournalClinical pharmacology and therapeutics
Volume48
Issue number3
StatePublished - Jan 1 1990

Fingerprint

Mephenytoin
Debrisoquin
Dapsone
Individuality
Aptitude
Pharmaceutical Preparations
Logistic Models
Enzymes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Gail May, D. ; Black, Carol M. ; Olsen, Nancy ; Csuka, Mary E. ; Bobo Tanner, S. ; Bellino, Lisa ; Porter, James A. ; Wilkinson, Grant R. ; Branch, Robert A. / Scleroderma is associated with differences in individual routes of drug metabolism : A study with dapsone, debrisoquin, and mephenytoin. In: Clinical pharmacology and therapeutics. 1990 ; Vol. 48, No. 3. pp. 286-295.
@article{a0db4e0c450a4dcba53f61c0842835c7,
title = "Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquin, and mephenytoin",
abstract = "Exposure to certain environmental agents may induce a scleroderma-like syndrome in a small proportion of individuals. Differences in susceptibility could involve metabolic activation of a protoxin, with affected patients having a greater converting ability. This possibility was investigated in 84 patients with scleroderma and 108 control subjects with in vivo probes of specific pathways of metabolism. Scleroderma was associated with reduced hydroxylating activity for dapsone and S-mephenytoin, whereas the ability to hydroxylate debrisoquin and N-acetyl dapsone was similar in both groups. Logistic regression confirmed these associations based on the shift in frequency distribution. Individuals who were poor metabolizers for mephenytoin and only modest N-hydroxylators of dapsone had a tenfold increased risk of scleroderma (p = 0.008). Thus this combined metabolic impairment may be causally involved in the development of scleroderma or, alternatively, the disease may produce inhibition of selected metabolizing enzymes in a subset of patients.",
author = "{Gail May}, D. and Black, {Carol M.} and Nancy Olsen and Csuka, {Mary E.} and {Bobo Tanner}, S. and Lisa Bellino and Porter, {James A.} and Wilkinson, {Grant R.} and Branch, {Robert A.}",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "48",
pages = "286--295",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

Gail May, D, Black, CM, Olsen, N, Csuka, ME, Bobo Tanner, S, Bellino, L, Porter, JA, Wilkinson, GR & Branch, RA 1990, 'Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquin, and mephenytoin', Clinical pharmacology and therapeutics, vol. 48, no. 3, pp. 286-295.

Scleroderma is associated with differences in individual routes of drug metabolism : A study with dapsone, debrisoquin, and mephenytoin. / Gail May, D.; Black, Carol M.; Olsen, Nancy; Csuka, Mary E.; Bobo Tanner, S.; Bellino, Lisa; Porter, James A.; Wilkinson, Grant R.; Branch, Robert A.

In: Clinical pharmacology and therapeutics, Vol. 48, No. 3, 01.01.1990, p. 286-295.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Scleroderma is associated with differences in individual routes of drug metabolism

T2 - A study with dapsone, debrisoquin, and mephenytoin

AU - Gail May, D.

AU - Black, Carol M.

AU - Olsen, Nancy

AU - Csuka, Mary E.

AU - Bobo Tanner, S.

AU - Bellino, Lisa

AU - Porter, James A.

AU - Wilkinson, Grant R.

AU - Branch, Robert A.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Exposure to certain environmental agents may induce a scleroderma-like syndrome in a small proportion of individuals. Differences in susceptibility could involve metabolic activation of a protoxin, with affected patients having a greater converting ability. This possibility was investigated in 84 patients with scleroderma and 108 control subjects with in vivo probes of specific pathways of metabolism. Scleroderma was associated with reduced hydroxylating activity for dapsone and S-mephenytoin, whereas the ability to hydroxylate debrisoquin and N-acetyl dapsone was similar in both groups. Logistic regression confirmed these associations based on the shift in frequency distribution. Individuals who were poor metabolizers for mephenytoin and only modest N-hydroxylators of dapsone had a tenfold increased risk of scleroderma (p = 0.008). Thus this combined metabolic impairment may be causally involved in the development of scleroderma or, alternatively, the disease may produce inhibition of selected metabolizing enzymes in a subset of patients.

AB - Exposure to certain environmental agents may induce a scleroderma-like syndrome in a small proportion of individuals. Differences in susceptibility could involve metabolic activation of a protoxin, with affected patients having a greater converting ability. This possibility was investigated in 84 patients with scleroderma and 108 control subjects with in vivo probes of specific pathways of metabolism. Scleroderma was associated with reduced hydroxylating activity for dapsone and S-mephenytoin, whereas the ability to hydroxylate debrisoquin and N-acetyl dapsone was similar in both groups. Logistic regression confirmed these associations based on the shift in frequency distribution. Individuals who were poor metabolizers for mephenytoin and only modest N-hydroxylators of dapsone had a tenfold increased risk of scleroderma (p = 0.008). Thus this combined metabolic impairment may be causally involved in the development of scleroderma or, alternatively, the disease may produce inhibition of selected metabolizing enzymes in a subset of patients.

UR - http://www.scopus.com/inward/record.url?scp=0025162357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025162357&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 286

EP - 295

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -